Cwm LLC Sells 292 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Cwm LLC trimmed its position in Henry Schein, Inc. (NASDAQ:HSIC) by 4.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,380 shares of the company’s stock after selling 292 shares during the quarter. Cwm LLC’s holdings in Henry Schein were worth $465,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of HSIC. GAMMA Investing LLC lifted its position in Henry Schein by 106.7% during the 3rd quarter. GAMMA Investing LLC now owns 2,069 shares of the company’s stock worth $151,000 after acquiring an additional 1,068 shares during the last quarter. Czech National Bank lifted its position in shares of Henry Schein by 5.8% during the 3rd quarter. Czech National Bank now owns 25,811 shares of the company’s stock worth $1,882,000 after purchasing an additional 1,409 shares during the last quarter. Handelsbanken Fonder AB boosted its stake in Henry Schein by 41.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 34,900 shares of the company’s stock valued at $2,544,000 after purchasing an additional 10,300 shares during the period. SG Americas Securities LLC boosted its stake in Henry Schein by 1,622.3% during the 3rd quarter. SG Americas Securities LLC now owns 458,828 shares of the company’s stock valued at $33,449,000 after purchasing an additional 432,187 shares during the period. Finally, Sanctuary Advisors LLC acquired a new stake in Henry Schein in the 2nd quarter valued at approximately $351,000. 96.62% of the stock is owned by institutional investors.

Henry Schein Stock Performance

Shares of NASDAQ:HSIC opened at $72.39 on Friday. The stock has a market capitalization of $9.27 billion, a price-to-earnings ratio of 24.46, a price-to-earnings-growth ratio of 1.98 and a beta of 0.86. The business’s fifty day moving average price is $70.40 and its two-hundred day moving average price is $69.88. Henry Schein, Inc. has a fifty-two week low of $60.01 and a fifty-two week high of $82.63. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.55 and a quick ratio of 0.90.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, August 6th. The company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.01. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. The business had revenue of $3.10 billion during the quarter, compared to analysts’ expectations of $3.27 billion. During the same quarter last year, the company posted $1.31 EPS. The firm’s revenue for the quarter was up .0% on a year-over-year basis. As a group, analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Lorelei Mcglynn sold 21,035 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the completion of the transaction, the senior vice president now owns 71,833 shares in the company, valued at $4,978,026.90. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

HSIC has been the subject of several research reports. Evercore ISI increased their price objective on Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a research report on Tuesday, October 8th. JPMorgan Chase & Co. decreased their price target on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. UBS Group cut their price objective on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Robert W. Baird reduced their target price on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Finally, Baird R W upgraded Henry Schein from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 22nd. One research analyst has rated the stock with a sell rating, six have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $77.50.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.